drugset / Trial / NCT00052156

Vaccine Therapy for Patients With Stage IV Melanoma

NCT00052156 ↗

Phase 3 Unknown 670 enrolled CancerVax Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase III study in patients with melanoma that has spread to the lymph nodes and/or a distant organ, and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

Timeline

Start
—
Primary completion
—
Completion
—

Outcome

Missed primary endpoint

paper BCG/Cv did not improve outcomes over BCG/placebo. PMID 29019177 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Canvaxin Vaccine — —

Indications